What does a prescriber think of biosimilars?

Oncologie

Volumn 13, Issue 5, 2011, Pages 234-238

  Aapro, M S ^a  

^a CLINIQUE DE GENOLIER   (Switzerland)

Author keywords

Biosimilars; Erythropoietins; Generic drugs; Growth factors; Prescription

Indexed keywords

BIOLOGICAL PRODUCT; BIOSIMILAR; GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG;

ARTICLE; BIOEQUIVALENCE; BREAST CANCER; CLINICAL PRACTICE; DRUG ACTIVITY; DRUG APPROVAL; DRUG EFFICACY; DRUG POTENCY; DRUG QUALITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ERYTHROCYTE APLASIA; FEBRILE NEUTROPENIA; HEALTH CARE COST; HEALTH CARE PERSONNEL; HOSPITALIZATION; HUMAN; IMMUNOGENICITY; LUNG CANCER; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; PRACTICE GUIDELINE; PRESCRIPTION; RISK FACTOR; TREATMENT DURATION;

EID: 79959664632     PISSN: 12923818     EISSN: 17652839     Source Type: Journal    
DOI: 10.1007/s10269-011-2015-y     Document Type: Article

References (26)

1. Aapro M, Cornes P, Abraham I (2011) Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia. J Oncol Pharm Pract [in press]
2. M. Aapro J. Van Erps K. MacDonald, et al. 2009 Managing cancer-related anaemia in congruence with the EORTC guidelines is an independent predictor of haemoglobin outcome: initial evidence from the RESPOND study Eur J Cancer 45 1 8 11 19058959 10.1016/j.ejca.2008.09.036
3. M. Aapro J. Van Erps K. MacDonald, et al. 2008 Promoting evidence-based management of anemia in cancer patients: background, development, and scientific validation of RESPOND, a web-based clinical guidance system based on the EORTC guidelines Crit Rev Oncol Hematol 65 32 42 17570677 10.1016/j.critrevonc.2007. 05.002 (Pubitemid 350225667)
4. M.S. Aapro J. Bohlius D.A. Cameron, et al. 2011 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours Eur J Cancer 47 1 8 32 21095116 10.1016/j.ejca.2010.10.013 1:CAS:528:DC%2BC3cXhsFyltLbE
5. D. Almenar D. Mayans O. Juan, et al. 2009 Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain - results of the LEARN study Eur J Cancer Care 18 280 286 10.1111/j.1365-2354.2008.00959.x 1:STN:280: DC%2BD1MzjsFansQ%3D%3D
6. C. Brockmeyer A. Seidl 2009 Binocrit: assessment of quality, safety and efficacy of biopharmaceuticals Eur J Hosp Pharm Prac 15 2 34 40
7. A. Decollogny Y. Eggli P. Halfon T.M. Lufkin 2011 Determinants of generic drug substitution in Switzerland BMC Health Serv Res 11 17 21269426 10.1186/1472-6963-11-17
8. M. Del Tacca G. Pasqualetti A. Di Paolo, et al. 2009 Lack of pharmacokinetic bioequivalence between generic and branded amoxicillin formulations. A post-marketing clinical study on healthy volunteers Br J Clin Pharmacol 68 34 42 19660001 10.1111/j.1365-2125.2009.03399.x
9. A.G. Dupont F. Heller 2009 Generics and cost-effective prescribing in Belgium: does bioequivalence always translate in therapeutic equivalence? Acta Clin Belg 64 406 414 19999388 1:STN:280:DC%2BD1MfitFajtA%3D%3D
10. EMEA. Questions and Answers on biosimilar medicines (similar biological medicinal products). http://www.ema.europa.eu/pdfs/human/pcwp/7456206en.pdf.2008 [last accessed: 8th March 2011].
11. C. Falandry M. Campone Cartron, et al. 2010 Trends in G-CSF use in 990 patients after EORTC and ASCO guidelines Eur J Cancer 46 2389 2398 20732287 10.1016/j.ejca.2010.04.031 1:STN:280:DC%2BC3cjnslChtg%3D%3D
12. P. Gascón M. Aapro H. Ludwig, et al. 2011 Background and methodology of MONITOR-GCSF, a pharmacoepidemiological study of the multi-level determinants, predictors, and clinical outcomes of febrile neutropenia prophylaxis with biosimilar granulocyte-colony stimulating factor filgrastim Crit Rev Oncol Hematol 77 184 197 20189821 10.1016/j.critrevonc.2010.01.014
13. P. Gascón M. Aapro H. Ludwig, et al. 2011 Update on the MONITOR-GCSF study of biosimilar filgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia in cancer patients: Protocol amendments Crit Rev Oncol Hematol 77 198 200 21377576 10.1016/j.critrevonc.2011.01.006
14. A.A. Genazzani F. Pattarino 2008 Difficulties in the production of identical drug products from a pharmaceutical technology viewpoint Drugs R D 9 65 72 18298125 10.2165/00126839-200809020-00001 1:CAS:528:DC%2BD1cXktlyjtr8%3D (Pubitemid 351311220)
15. B. Godman W. Shrank M. Andersen, et al. 2010 Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications Expert Rev Pharmacoecon Outcomes Res 10 707 722 21155704 10.1586/erp.10.72
16. P. Kanavos 2007 Do generics offer significant savings to the UK National Health Service? Curr Med Res Opin 23 105 116 17257472 10.1185/030079907X159506 (Pubitemid 46191676)
17. H.C. Margolese Y. Wolf J.E. Desmarais L. Beauclair 2010 Loss of response after switching from brand name to generic formulations: three cases and a discussion of key clinical considerations when switching Int Clin Psychopharmacol 25 3 180 182 20216221 10.1097/YIC.0b013e328337910b
18. H. Mellstedt D. Niederwieser H. Ludwig 2008 The challenge of biosimilars Ann Oncol 19 411 419 17872902 10.1093/annonc/mdm345 1:STN:280: DC%2BD1c7ksVSksQ%3D%3D (Pubitemid 351325660)
19. J.D. Rizzo M. Brouwers P. Hurley, et al. 2010 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer J Clin Oncol 28 4996 5010 20975064 10.1200/JCO.2010.29.2201
20. H. Schellekens 2009 Assessing the bioequivalence of biosimilars: The Retacrit? case Drug Discov Today 14 9-10 495 499 19429509 10.1016/j.drudis.2009. 02.003 1:CAS:528:DC%2BD1MXltlKru7c%3D
21. H. Schellekens E. Klinger S. Mühlebach, et al. 2011 The therapeutic equivalence of complex drugs Regul Toxicol Pharmacol 59 176 183 20951177 10.1016/j.yrtph.2010.09.021 1:CAS:528:DC%2BC3MXhtVSlsbY%3D
22. H. Schellekens E. Moors 2010 Clinical comparability and European biosimilar regulations Nat Biotechnol 28 1 28 31 20062035 10.1038/nbt0110-28 1:CAS:528:DC%2BC3cXis1CisQ%3D%3D
23. D. Schrijvers H. De Samblanx F. Roila ESMO Guidelines Working Group 2010 Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use Ann Oncol 21 Suppl5 v244 v247 20555090 10.1093/annonc/mdq202
24. J. Van Erps M. Aapro K. McDonald, et al. 2010 Promoting evidence-based management of anemia in cancer patients: concurrent and discriminant validity of RESPOND, a web-based clinical guidance system based on the EORTC guidelines for supportive care in cancer Support Care Cancer 18 847 858 19904563 10.1007/s00520-009-0718-z
25. D. Weycker J. Hackett J. Edelsberg, et al. 2006 Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization? Ann Pharmacother 40 402 407 16492793 10.1345/aph.1G516 1:CAS:528: DC%2BD28XjsFagsr4%3D
26. www.ema.europa.eu/docs/en-GB/document-library/Public-statement/2009/11/ WC500011292.pdf [last accessed March 16, 2011]